JP2020534375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534375A5 JP2020534375A5 JP2020538753A JP2020538753A JP2020534375A5 JP 2020534375 A5 JP2020534375 A5 JP 2020534375A5 JP 2020538753 A JP2020538753 A JP 2020538753A JP 2020538753 A JP2020538753 A JP 2020538753A JP 2020534375 A5 JP2020534375 A5 JP 2020534375A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- membered
- saturated
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 144
- 229910052757 nitrogen Inorganic materials 0.000 claims description 82
- 125000005842 heteroatom Chemical group 0.000 claims description 79
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 70
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 70
- 229910052760 oxygen Inorganic materials 0.000 claims description 70
- 239000001301 oxygen Substances 0.000 claims description 70
- 229920006395 saturated elastomer Polymers 0.000 claims description 70
- 229910052717 sulfur Inorganic materials 0.000 claims description 70
- 239000011593 sulfur Substances 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 125000002619 bicyclic group Chemical group 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- 125000001931 aliphatic group Chemical group 0.000 claims description 25
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 229910052712 strontium Inorganic materials 0.000 claims description 10
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 206010018338 Glioma Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 125000005605 benzo group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000005400 Synovial Cyst Diseases 0.000 claims description 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 210000004214 philadelphia chromosome Anatomy 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000017701 Endocrine disease Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010023256 Juvenile melanoma benign Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 201000004458 Myoma Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 201000004404 Neurofibroma Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010037127 Pseudolymphoma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002518 glial effect Effects 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 2
- 230000036244 malformation Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000010943 meningeal sarcoma Diseases 0.000 claims description 2
- 201000003776 meninges sarcoma Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 206010042863 synovial sarcoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 230000002861 ventricular Effects 0.000 claims description 2
- 0 C*N(C)CC(*(C)C)=O Chemical compound C*N(C)CC(*(C)C)=O 0.000 description 4
- 102000015367 CRBN Human genes 0.000 description 4
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 4
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023175302A JP7818560B2 (ja) | 2017-09-22 | 2023-10-10 | タンパク質分解剤およびそれらの使用 |
| JP2025136973A JP2025170324A (ja) | 2017-09-22 | 2025-08-20 | タンパク質分解剤およびそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562206P | 2017-09-22 | 2017-09-22 | |
| US62/562,206 | 2017-09-22 | ||
| US201762610403P | 2017-12-26 | 2017-12-26 | |
| US62/610,403 | 2017-12-26 | ||
| US201862714527P | 2018-08-03 | 2018-08-03 | |
| US62/714,527 | 2018-08-03 | ||
| PCT/US2018/052242 WO2019060742A1 (en) | 2017-09-22 | 2018-09-21 | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023175302A Division JP7818560B2 (ja) | 2017-09-22 | 2023-10-10 | タンパク質分解剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534375A JP2020534375A (ja) | 2020-11-26 |
| JP2020534375A5 true JP2020534375A5 (OSRAM) | 2021-10-21 |
| JP7366031B2 JP7366031B2 (ja) | 2023-10-20 |
Family
ID=65810510
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538753A Active JP7366031B2 (ja) | 2017-09-22 | 2018-09-21 | タンパク質分解剤およびそれらの使用 |
| JP2023175302A Active JP7818560B2 (ja) | 2017-09-22 | 2023-10-10 | タンパク質分解剤およびそれらの使用 |
| JP2025136973A Pending JP2025170324A (ja) | 2017-09-22 | 2025-08-20 | タンパク質分解剤およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023175302A Active JP7818560B2 (ja) | 2017-09-22 | 2023-10-10 | タンパク質分解剤およびそれらの使用 |
| JP2025136973A Pending JP2025170324A (ja) | 2017-09-22 | 2025-08-20 | タンパク質分解剤およびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11623932B2 (OSRAM) |
| EP (2) | EP3684365A4 (OSRAM) |
| JP (3) | JP7366031B2 (OSRAM) |
| AU (2) | AU2018338314B2 (OSRAM) |
| CA (2) | CA3283159A1 (OSRAM) |
| IL (4) | IL273432B (OSRAM) |
| MX (3) | MX2020003190A (OSRAM) |
| WO (1) | WO2019060742A1 (OSRAM) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| ES2941818T3 (es) | 2017-12-21 | 2023-05-25 | Ribon Therapeutics Inc | Quinazolinonas como inhibidores de PARP14 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3817822A4 (en) * | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CN112533898A (zh) | 2018-07-31 | 2021-03-19 | 日商泛美克斯股份有限公司 | 杂环化合物 |
| PT3860998T (pt) | 2018-10-05 | 2024-04-02 | Annapurna Bio Inc | Compostos e composições para o tratamento de condições associadas à atividade do recetor apj |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| US11485750B1 (en) * | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
| MA55628A (fr) | 2019-04-12 | 2022-02-16 | C4 Therapeutics Inc | Agents de dégradation tricycliques d'ikaros et d'aiolos |
| CN110058014B (zh) * | 2019-04-25 | 2021-06-04 | 中国科学院化学研究所 | 用于筛选lrpprc调控剂的产品及鉴定lrpprc调控剂的方法 |
| JP7289510B2 (ja) * | 2019-05-08 | 2023-06-12 | 国立大学法人高知大学 | 認知症治療薬のスクリーニング方法 |
| WO2020236901A1 (en) * | 2019-05-20 | 2020-11-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp) |
| WO2020251971A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| CN114007652A (zh) * | 2019-06-18 | 2022-02-01 | 达纳-法伯癌症研究公司 | 小分子靶向溴/乙酰蛋白及其用途 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| ES3061133T3 (en) | 2019-08-26 | 2026-03-31 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| WO2021041942A1 (en) * | 2019-08-28 | 2021-03-04 | University Of Kentucky Research Foundation | Collagen p4h1 inhibitor and its use |
| CN110596403B (zh) * | 2019-09-17 | 2022-12-16 | 中山大学附属第一医院 | 用于卵巢癌诊断的特异性蛋白标记物及制备方法 |
| US12310975B2 (en) | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| CN110749733B (zh) * | 2019-12-06 | 2021-08-27 | 四川大学华西医院 | Tgif2ly自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| EP4072591A4 (en) | 2019-12-10 | 2024-06-05 | Kymera Therapeutics, Inc. | IRAQ DEGRADER AND USES THEREOF |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4076001A4 (en) | 2019-12-17 | 2023-12-20 | Orionis Biosciences, Inc. | MODULATION OF PROTEIN DEGRADATION |
| WO2021127586A1 (en) * | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
| KR20210103973A (ko) * | 2020-02-14 | 2021-08-24 | 보로노이 주식회사 | 단백질 키나아제 분해 유도 화합물 및 이의 용도 |
| CN111214664B (zh) * | 2020-02-24 | 2022-02-11 | 大连医科大学 | USP2和HSP90抑制剂联合使用抑制ErbB2阳性乳腺癌生长的应用 |
| IL295709A (en) | 2020-03-05 | 2022-10-01 | C4 Therapeutics Inc | Compounds for targeted degradation of brd9 |
| EP3878847A1 (en) * | 2020-03-13 | 2021-09-15 | Centre Régional de Lutte contre le Cancer - Centre François Baclesse | Bcl-2 family proteins modulating compounds for cancer treatment |
| WO2021185291A1 (zh) * | 2020-03-17 | 2021-09-23 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
| CN115776891A (zh) * | 2020-03-17 | 2023-03-10 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| IL296451B2 (en) | 2020-03-19 | 2026-05-01 | Kymera Therapeutics Inc | MDM2 joints and their uses |
| US12053469B2 (en) | 2020-03-21 | 2024-08-06 | Arvinas Operations, Inc. | Indazole based compounds and associated methods of use |
| CA3172589A1 (en) * | 2020-05-21 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Piperidine-2,6-diones as small molecule degraders of helios and methods of use |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CA3173629A1 (en) | 2020-06-19 | 2021-12-13 | Cosimo Dolente | Braf degraders |
| KR102654220B1 (ko) * | 2020-07-07 | 2024-04-04 | 한국식품연구원 | Cmip 억제제를 포함하는 지방간 질환의 예방 또는 치료용 약학적 조성물 |
| US20230248834A1 (en) * | 2020-07-16 | 2023-08-10 | Beigene, Ltd. | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use |
| JP7692128B2 (ja) * | 2020-07-17 | 2025-06-13 | 国立医薬品食品衛生研究所長 | 新規化合物及び医薬組成物 |
| JP2023545730A (ja) * | 2020-10-07 | 2023-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｓｔａｔ分解剤およびそれらの使用 |
| CN116744929A (zh) * | 2020-11-20 | 2023-09-12 | 福霍恩治疗公司 | 化合物及其用途 |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2022147465A1 (en) | 2020-12-30 | 2022-07-07 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN112899351B (zh) * | 2021-02-03 | 2022-08-26 | 东华大学 | 一种双重荧光定量pcr检测pdx模型小鼠细胞浸润状态试剂盒 |
| CN116867494A (zh) | 2021-02-15 | 2023-10-10 | 凯麦拉医疗公司 | Irak4降解剂和其用途 |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| JP2024512501A (ja) | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| WO2022216675A1 (en) * | 2021-04-06 | 2022-10-13 | Believe In A Cure, Inc. | [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)- amino]-acetic acid for use in increasing foxg1 expression |
| CA3214806A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN113186273B (zh) * | 2021-05-13 | 2023-02-21 | 中国人民解放军总医院第一医学中心 | 一种用于预测P2Y12受体拮抗剂抗血小板疗效的circRNA检测试剂盒及其应用 |
| JP2024523839A (ja) | 2021-06-08 | 2024-07-02 | シーフォー セラピューティクス， インコーポレイテッド | 突然変異体ｂｒａｆを分解する療法薬 |
| JP2024522768A (ja) * | 2021-06-16 | 2024-06-21 | バイオセリックス， インコーポレイテッド | Ｓｏｓ１タンパク質分解剤、その医薬組成物及びそれらの治療的応用 |
| CA3223322A1 (en) * | 2021-06-21 | 2022-12-29 | Gesine Kerstin Veits | Degrader compounds and uses thereof |
| US20250129047A1 (en) | 2021-07-04 | 2025-04-24 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| CN113637750A (zh) * | 2021-07-16 | 2021-11-12 | 宁波市第一医院 | 急性髓系白血病的辅助诊断、预后诊断或危险度分层标记物及其应用 |
| CN113817818B (zh) * | 2021-10-22 | 2023-04-28 | 常州市第二人民医院 | 用于诊断过敏性气道炎症的工具 |
| CN113817833B (zh) * | 2021-10-26 | 2022-09-30 | 常州国药医学检验实验室有限公司 | 一种基于荧光定量pcr技术的检测宫颈细胞基因甲基化的试剂盒与应用 |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| WO2023107706A1 (en) * | 2021-12-11 | 2023-06-15 | Kymera Therapeutics, Inc. | Stat3 degraders and uses thereof |
| EP4450490A4 (en) * | 2021-12-14 | 2025-04-16 | Prazer Therapeutics Inc. | Novel compound for degrading a target protein or polypeptide by polyubiquitination |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| CN114656509B (zh) * | 2022-04-08 | 2024-05-24 | 国科温州研究院(温州生物材料与工程研究所) | 一种氮杂环卡宾-金钯合金纳米粒子及其制备方法和应用 |
| US20250333733A1 (en) * | 2022-05-19 | 2025-10-30 | University Of Puerto Rico | Novel targets against ovarian cancer |
| JP2025518252A (ja) | 2022-06-02 | 2025-06-12 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Ｂｃｌ６を阻害又は分解する化合物及びその医薬的な応用 |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| EP4543854A1 (en) * | 2022-06-22 | 2025-04-30 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| AU2023298115A1 (en) | 2022-06-27 | 2025-01-16 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and use thereof |
| WO2024006776A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
| CA3265344A1 (en) * | 2022-08-19 | 2024-02-22 | University Of Louisiana Monroe | METHOD FOR THE DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING ZINC FINGER-PATTERNED PROTEIN TYPE 1 ANTIBODIES |
| EP4600246A4 (en) | 2022-10-03 | 2026-01-07 | Public Univ Corp Yokohama City Univ | BICYCLIC IMIDAZOPYRIDINE DERIVATIVES |
| CN115639306B (zh) * | 2022-12-26 | 2023-03-28 | 四川大学华西医院 | 一种快速检测临床样本中抗癫痫药物浓度的方法 |
| AU2024211840A1 (en) | 2023-01-24 | 2025-07-03 | Daiichi Sankyo Company, Limited | Substituted benzene compound |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024173718A2 (en) * | 2023-02-16 | 2024-08-22 | St. Jude Children's Research Hospital | Heterobifunctional binders of klhdc2 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| CN117205322A (zh) * | 2023-09-08 | 2023-12-12 | 河南大学 | Fer1l6基因在糖尿病防治中的应用 |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| AU2024352092A1 (en) | 2023-09-28 | 2026-04-09 | Arvinas Operations, Inc. | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2) |
| WO2025070690A1 (ja) | 2023-09-29 | 2025-04-03 | 第一三共株式会社 | ３－フェニルプロピルアミン誘導体 |
| CN121941690A (zh) * | 2023-10-03 | 2026-04-28 | Paq医疗公司 | Kras蛋白水解靶向嵌合体 |
| WO2025096984A1 (en) * | 2023-11-02 | 2025-05-08 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| CN117756818B (zh) * | 2023-12-12 | 2025-04-29 | 北京医院 | 一种戊二酰亚胺类化合物及其制备方法和应用 |
| WO2025194014A1 (en) | 2024-03-15 | 2025-09-18 | Dem Biopharma, Inc. | Hetero aryl modulators of apmap and uses thereof |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| WO2026032430A1 (en) * | 2024-08-09 | 2026-02-12 | Nanjing Huanbo Biotechnology Co., Ltd. | Use of a g protein-coupled receptor kinase 2 (grk2) degradation compound in lowering blood glucose, stimulating or increasing insulin secretion, or preventing or treating a disease or disorder related thereto |
| CN118702679B (zh) * | 2024-08-26 | 2024-10-29 | 四川大学华西医院 | 一种具有ezh2/brd4双靶点活性的化合物、药物组合物及其制备方法和用途 |
| CN120330336A (zh) * | 2025-03-19 | 2025-07-18 | 中南大学湘雅医院 | 一种用于宫颈癌和/或宫颈癌前病变检测的甲基化标志物组合及其应用、产品、检测装置、计算机可读存储介质、电子终端和计算机程序 |
| CN120794955A (zh) * | 2025-07-07 | 2025-10-17 | 四川伊诺唯新生物医药有限公司 | 一种irak4靶向蛋白降解剂关键中间体的制备方法 |
Family Cites Families (195)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5360811A (en) | 1990-03-13 | 1994-11-01 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents |
| JP3545461B2 (ja) | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| EA006227B1 (ru) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| DE10002509A1 (de) | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| AU2001241798A1 (en) | 2000-02-28 | 2001-09-12 | Sugen, Inc. | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| EP1322750A4 (en) | 2000-09-08 | 2004-09-29 | California Inst Of Techn | PROTEOLYSIS TARGET DRUG TARGET MEDICINE |
| US7071189B2 (en) | 2001-04-27 | 2006-07-04 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| US7425553B2 (en) | 2003-05-30 | 2008-09-16 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| CA2531069A1 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| JP4398263B2 (ja) | 2004-01-13 | 2010-01-13 | 富士通株式会社 | 経路設計方法 |
| EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP4801096B2 (ja) | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| EP2757099B1 (en) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| AU2006302179C1 (en) | 2005-10-07 | 2013-06-20 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| US7528143B2 (en) | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| DK1966130T3 (da) | 2005-12-23 | 2014-02-10 | Zealand Pharma As | Modificerede lysin-mimetiske forbindelser |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| RU2439074C2 (ru) | 2006-04-26 | 2012-01-10 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К) |
| PL2526933T3 (pl) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| US20100279316A1 (en) | 2007-01-19 | 2010-11-04 | Leonid Gorelik | Antibodies to Phosphorylated IRAK4 |
| US8486941B2 (en) | 2007-03-12 | 2013-07-16 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2217716A4 (en) | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS |
| CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| TWI444382B (zh) | 2008-03-11 | 2014-07-11 | Incyte Corp | 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物 |
| CN102083429B (zh) | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8921037B2 (en) | 2008-12-16 | 2014-12-30 | Bo Han | PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| US8114621B2 (en) | 2010-03-12 | 2012-02-14 | Saladax Biomedical Inc. | Lenalidomide and thalidomide immunoassays |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| EP2588129A4 (en) | 2010-06-30 | 2014-07-09 | Univ Brandeis | ON SMALL MOLECULES TARGETED PROTEIN REMOVAL |
| CN102985426B (zh) | 2010-07-13 | 2015-10-07 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| HUE037860T2 (hu) | 2010-11-19 | 2018-09-28 | Ligand Pharm Inc | Heterociklusos aminok és alkalmazásuk |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012084704A1 (en) | 2010-12-20 | 2012-06-28 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| EP2663312B1 (en) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US9169260B2 (en) | 2011-03-22 | 2015-10-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| NO2694640T3 (OSRAM) | 2011-04-15 | 2018-03-17 | ||
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| US9221809B2 (en) | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104582705A (zh) | 2012-01-10 | 2015-04-29 | 林伯士艾瑞斯公司 | 白介素-1受体相关激酶(irak)抑制剂和其用途 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| JP6109195B2 (ja) | 2012-01-13 | 2017-04-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SG11201500005SA (en) | 2012-07-10 | 2015-01-29 | Ares Trading Sa | Pyrimidine pyrazolyl derivatives |
| HK1210696A1 (en) | 2012-07-11 | 2016-05-06 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014011911A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN104902959A (zh) | 2012-07-11 | 2015-09-09 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| JP6302912B2 (ja) | 2012-09-19 | 2018-03-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ２−オキソ−２，３，４，５−テトラヒドロ−１ｈ−ベンゾ［ｂ］ジアゼピン及びがんの治療におけるその使用 |
| US9586948B2 (en) | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| EP2903617B1 (en) | 2012-10-08 | 2019-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| HUE032863T2 (en) | 2013-02-07 | 2017-11-28 | Merck Patent Gmbh | Piridazinonamid derivatives |
| RU2660435C2 (ru) | 2013-02-07 | 2018-07-06 | Мерк Патент Гмбх | Макроциклические производные пиридазинона |
| WO2014143672A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases |
| WO2015048281A1 (en) | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2015068856A1 (en) | 2013-11-08 | 2015-05-14 | Takeda Pharmaceutical Company Limited | Pyrazole for the treatment autoimmune disorders |
| US10053431B2 (en) | 2013-11-18 | 2018-08-21 | Hoffmann-La Roche Inc. | Tetrahydro-benzodiazepinones |
| CN105764514B (zh) | 2013-11-27 | 2019-07-12 | 圣诺康生命科学公司 | 作为tam族激酶抑制剂的氨基吡啶衍生物 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| AR098991A1 (es) | 2014-01-03 | 2016-06-22 | Bristol Myers Squibb Co | Compuestos de nicotinamida sustituida con heteroarilo |
| BR112016015983A2 (pt) | 2014-01-10 | 2017-08-08 | Aurigene Discovery Tech Ltd | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica |
| SMT202400142T1 (it) | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| MA39749A (fr) | 2014-03-17 | 2017-01-25 | Hoffmann La Roche | Dérivés de pipéridine-dione |
| WO2015150995A1 (en) | 2014-04-04 | 2015-10-08 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CN119591582A (zh) | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| CN106413715A (zh) | 2014-04-22 | 2017-02-15 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| KR20170016500A (ko) | 2014-06-20 | 2017-02-13 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 저해제로서의 치환된 인다졸 화합물 |
| EP3160486B1 (en) | 2014-06-27 | 2020-11-18 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| AR101229A1 (es) | 2014-07-18 | 2016-11-30 | Biogen Ma Inc | Agentes inhibidores de irak4 |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| EP3200789B1 (en) | 2014-09-30 | 2019-11-06 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US9943516B2 (en) | 2014-09-30 | 2018-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| EP3200788B1 (en) | 2014-09-30 | 2019-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| ES2772133T3 (es) | 2014-11-20 | 2020-07-07 | Merck Patent Gmbh | Compuestos heteroarilo como inhibidores de IRAK y sus usos |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| WO2016144848A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrrolotriazine inhibitors of irak4 activity |
| EP3268003B1 (en) | 2015-03-12 | 2020-07-29 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
| WO2016144846A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| US10040798B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of IRAK4 activity |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| PT3286181T (pt) | 2015-04-22 | 2021-04-05 | Rigel Pharmaceuticals Inc | Compostos de pirazol e método para preparar e usar os compostos |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| KR20240119196A (ko) | 2015-06-04 | 2024-08-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드계 조절인자 및 관련된 이용 방법 |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| CN105085620B (zh) | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN108137507A (zh) | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| AU2016293441A1 (en) | 2015-07-15 | 2018-02-01 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as IRAK-4 inhibitors |
| CN108024971A (zh) | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| RS61719B1 (sr) | 2015-08-27 | 2021-05-31 | Pfizer | Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4 |
| EP3350170B1 (en) | 2015-09-18 | 2022-01-26 | Merck Patent GmbH | Heteroaryl compounds as irak inhibitors and uses thereof |
| EP3350177B1 (en) | 2015-09-18 | 2021-07-07 | Merck Patent GmbH | Heteroaryl compounds as irak inhibitors and uses thereof |
| WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| CN108473498B (zh) | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| WO2017117474A1 (en) | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| WO2017117473A1 (en) | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional molescules for her3 degradation and methods of use |
| ES2904557T3 (es) | 2016-01-20 | 2022-04-05 | Biogen Ma Inc | Agentes inhibidores de irak4 |
| CA3017740A1 (en) | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Small molecules against cereblon to enhance effector t cell function |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246453A1 (en) | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| JP2019515932A (ja) * | 2016-04-29 | 2019-06-13 | アスター バイオテック リミテッド ライアビリティ カンパニー | チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物 |
| EP3455219A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017207385A1 (de) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3475263B1 (en) | 2016-06-27 | 2022-12-28 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019196309A (ja) | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2018089736A1 (en) | 2016-11-10 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| CA3042731A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| TWI733982B (zh) | 2017-02-16 | 2021-07-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| RS62430B1 (sr) | 2017-05-11 | 2021-11-30 | Bristol Myers Squibb Co | Tienopiridini i benzotiofeni korisni kao irak4 inhibitori |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE |
| EP3700901A1 (en) | 2017-10-24 | 2020-09-02 | Genentech, Inc. | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| CA3090417A1 (en) | 2018-02-23 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Small molecules for inducing selective protein degradation and uses thereof |
| US20220356185A1 (en) | 2018-07-06 | 2022-11-10 | Kymera Therapeutics, Inc. | Mertk degraders and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
-
2018
- 2018-09-21 JP JP2020538753A patent/JP7366031B2/ja active Active
- 2018-09-21 US US16/649,732 patent/US11623932B2/en active Active
- 2018-09-21 CA CA3283159A patent/CA3283159A1/en active Pending
- 2018-09-21 WO PCT/US2018/052242 patent/WO2019060742A1/en not_active Ceased
- 2018-09-21 IL IL273432A patent/IL273432B/en unknown
- 2018-09-21 IL IL295603A patent/IL295603B2/en unknown
- 2018-09-21 IL IL322809A patent/IL322809A/en unknown
- 2018-09-21 MX MX2020003190A patent/MX2020003190A/es unknown
- 2018-09-21 CA CA3076613A patent/CA3076613A1/en active Pending
- 2018-09-21 AU AU2018338314A patent/AU2018338314B2/en active Active
- 2018-09-21 IL IL307995A patent/IL307995A/en unknown
- 2018-09-21 EP EP18857581.5A patent/EP3684365A4/en active Pending
- 2018-09-21 EP EP25195747.8A patent/EP4624467A3/en active Pending
-
2020
- 2020-03-20 MX MX2022013526A patent/MX2022013526A/es unknown
- 2020-03-20 MX MX2023015185A patent/MX2023015185A/es unknown
-
2022
- 2022-06-10 US US17/837,449 patent/US20230115184A1/en active Pending
-
2023
- 2023-10-10 JP JP2023175302A patent/JP7818560B2/ja active Active
-
2025
- 2025-03-12 AU AU2025201796A patent/AU2025201796A1/en not_active Abandoned
- 2025-08-19 US US19/304,052 patent/US20260085075A1/en active Pending
- 2025-08-20 JP JP2025136973A patent/JP2025170324A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273432B (en) | Protein compounds and their uses | |
| JP2022527114A5 (OSRAM) | ||
| CN107074768B (zh) | 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物 | |
| JP6784348B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| KR20250029954A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| KR102469506B1 (ko) | Fgfr 키나제 조정제로서 유용한 퀴녹살린 유도체 | |
| TWI363627B (en) | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | |
| JP2022523201A (ja) | Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体 | |
| RU2000108431A (ru) | Ингибиторы поли(адф-рибоза) полимеразы ("parp"), способы и фармацевтические композиции для лечения повреждения нервной или сердечно-сосудистой ткани | |
| AU2017273120A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| JP2021518335A (ja) | Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のシクロペンタン−ベースのモジュレーター | |
| CN111565717A (zh) | Myst家族组蛋白乙酰转移酶抑制剂 | |
| UA114894C2 (uk) | Інгібітори nedd8-активуючого ферменту | |
| JP6970684B2 (ja) | クマリン骨格を有するスルホンアミド誘導体 | |
| JP2017101055A (ja) | テトラヒドロピラニルメチル基を有するピリドン誘導体 | |
| WO2022262797A1 (en) | Combination of an erk inhibitor and a kras inhibitor and uses thereof | |
| CN113939285A (zh) | Pin1活性的调节剂及其用途 | |
| EP4352054A1 (en) | Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same | |
| JP2023529926A (ja) | Ｇｃｎ２阻害剤として有用な４－エチニルピリジン誘導体 | |
| TW202413377A (zh) | 吲唑巨環化合物及其用途 | |
| JP6831324B2 (ja) | 特定のタンパク質キナーゼ阻害剤 | |
| CN102333781B (zh) | 三环吡唑并嘧啶衍生物 | |
| EP2928864A1 (en) | New derivatives of indole for the treatment of cancer, viral infections and lung diseases | |
| WO2017070464A1 (en) | Cofactor analogs as methyltransferase inhibitors for treating cancer | |
| Dashyan et al. | New bisthioalkyl substituted thieno [3, 2-d] pyrimidines: synthesis and antitumor activity. |